12 Month Price Forecast For DOCS
Distance to DOCS Price Forecasts
DOCS Price Momentum
🤔 Considering Doximity (DOCS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 1:37 PM UTC
DOCS Analyst Ratings & Price Targets
Based on our analysis of 26 Wall Street analysts, DOCS has a neutral consensus with a median price target of $71.00 (ranging from $55.00 to $90.00). The overall analyst rating is Buy (7.2/10). Currently trading at $77.07, the median forecast implies a -7.9% downside. This outlook is supported by 7 Buy, 12 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Cherny at Leerink Partners, projecting a 16.8% upside. Conversely, the most conservative target is provided by Stan Berenshteyn at Wells Fargo, suggesting a 28.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DOCS Analyst Consensus
DOCS Price Target Range
Latest DOCS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DOCS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 10, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $65.00 |
| Feb 10, 2025 | Goldman Sachs | David Roman | Neutral | Maintains | $80.00 |
| Feb 7, 2025 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $55.00 |
| Feb 7, 2025 | Raymond James | Brian Peterson | Outperform | Reiterates | $83.00 |
| Feb 7, 2025 | Needham | Scott Berg | Buy | Maintains | $82.00 |
| Feb 7, 2025 | Canaccord Genuity | Richard Close | Hold | Maintains | $71.00 |
| Feb 7, 2025 | Leerink Partners | Michael Cherny | Outperform | Upgrade | $90.00 |
| Jan 13, 2025 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $43.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $65.00 |
| Jan 6, 2025 | B of A Securities | Allen Lutz | Neutral | Maintains | $57.00 |
| Dec 20, 2024 | Stephens & Co. | Jeff Garro | Equal-Weight | Initiates | $55.00 |
| Dec 4, 2024 | Mizuho | Steven Valiquette | Neutral | Initiates | $55.00 |
| Nov 21, 2024 | JP Morgan | Anne Samuel | Neutral | Maintains | $48.00 |
| Nov 15, 2024 | Goldman Sachs | David Roman | Neutral | Initiates | $58.00 |
| Nov 14, 2024 | Morgan Stanley | Ricky Goldwasser | Equal-Weight | Upgrade | $53.00 |
| Nov 14, 2024 | Truist Securities | Jailendra Singh | Hold | Maintains | $49.00 |
| Nov 13, 2024 | Canaccord Genuity | Richard Close | Hold | Downgrade | $60.00 |
| Nov 11, 2024 | Barclays | Stephanie Davis | Overweight | Maintains | $75.00 |
| Nov 8, 2024 | Raymond James | Brian Peterson | Outperform | Reiterates | $65.00 |
| Nov 8, 2024 | Keybanc | Scott Schoenhaus | Overweight | Upgrade | $70.00 |
Stocks Similar to Doximity, Inc.
The following stocks are similar to Doximity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Doximity, Inc. (DOCS) Financial Data
Doximity, Inc. has a market capitalization of $14.46B with a P/E ratio of 77.1x. The company generates $550.17M in trailing twelve-month revenue with a 36.6% profit margin.
Revenue growth is +24.6% quarter-over-quarter, while maintaining an operating margin of +47.5% and return on equity of +21.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Doximity, Inc. (DOCS) Company Overview
About Doximity, Inc.
Cloud-based platform for medical professionals.
Doximity generates revenue through subscriptions and advertising by offering digital tools that facilitate collaboration, career management, and administrative efficiency for healthcare providers. The platform primarily serves a range of medical professionals, enabling them to enhance their practice and streamline operations.
Founded in 2010 and headquartered in San Francisco, Doximity has established itself as a vital resource for healthcare professionals in the U.S., allowing for virtual patient visits and providing access to medical news and research.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
827
CEO
Mr. Jeffrey A. Tangney
Country
United States
IPO Year
2021
Website
www.doximity.comDoximity, Inc. (DOCS) Latest News & Analysis
Doximity (DOCS) is being evaluated as a potential top stock pick for momentum investors. Further analysis is needed to determine its suitability.
The inquiry into Doximity's potential as a momentum stock signals investor interest, which could influence stock performance and attract trading activity.
Doximity (DOCS) shares are experiencing upward momentum, supported by positive earnings estimate revisions, suggesting potential for further gains.
Rising earnings estimate revisions signal improving profitability for Doximity, potentially leading to higher stock prices and increased investor confidence.
Doximity (DOCS) shows strong financial growth potential, indicating it may outperform the market.
Doximity's above-average financial growth signals strong potential for market outperformance, indicating a favorable investment opportunity and possible increased returns.
Doximity, Inc. shows strong Q3 earnings, with DOCS stock up 56% since the last analysis. Updated DCF valuation suggests a price target of $90, indicating a 14% upside potential.
Doximity's strong Q3 earnings and an updated price target of $90 signal growth potential, outperforming the S&P 500, which can attract investor interest and boost confidence in the stock.
Doximity's Q3 fiscal 2025 revenue rose 25% to $168.6 million, surpassing analysts' expectations and guidance.
Doximity's strong Q3 performance and raised guidance signal robust growth, likely boosting investor confidence and potentially driving stock prices higher.
Doximity shares rose significantly after reporting Q3 results that exceeded revenue expectations and provided strong guidance, described by analysts as a "statement type of quarter."
Doximity's strong quarterly results and positive guidance signal robust growth, enhancing investor confidence and potentially driving share prices higher.
Frequently Asked Questions About DOCS Stock
What is Doximity, Inc.'s (DOCS) stock forecast for 2025?
Based on our analysis of 26 Wall Street analysts, Doximity, Inc. (DOCS) has a median price target of $71.00. The highest price target is $90.00 and the lowest is $55.00.
Is DOCS stock a good investment in 2025?
According to current analyst ratings, DOCS has 7 Buy ratings, 12 Hold ratings, and 0 Sell ratings. The stock is currently trading at $77.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for DOCS stock?
Wall Street analysts predict DOCS stock could reach $71.00 in the next 12 months. This represents a -7.9% decrease from the current price of $77.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Doximity, Inc.'s business model?
Doximity generates revenue through subscriptions and advertising by offering digital tools that facilitate collaboration, career management, and administrative efficiency for healthcare providers. The platform primarily serves a range of medical professionals, enabling them to enhance their practice and streamline operations.
What is the highest forecasted price for DOCS Doximity, Inc.?
The highest price target for DOCS is $90.00 from Michael Cherny at Leerink Partners, which represents a 16.8% increase from the current price of $77.07.
What is the lowest forecasted price for DOCS Doximity, Inc.?
The lowest price target for DOCS is $55.00 from Stan Berenshteyn at Wells Fargo, which represents a -28.6% decrease from the current price of $77.07.
What is the overall DOCS consensus from analysts for Doximity, Inc.?
The overall analyst consensus for DOCS is neutral. Out of 26 Wall Street analysts, 7 rate it as Buy, 12 as Hold, and 0 as Sell, with a median price target of $71.00.
How accurate are DOCS stock price projections?
Stock price projections, including those for Doximity, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
